Long-term Results of Treatment of Patients with Non-proliferative Diabetic Retinopathy Angioprotectors
Purpose: Optimization of approaches to the treatment of early stages diabetic retinopathy based on modern diagnosis and monitoring of patients with type 2 diabetes.Patients and methods: It was examined 90 patients (180 eyes) with type 2 diabetes with DR: women (74.4%) and men (25.6%), age 63,7±2,3 y...
Main Author: | |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Ophthalmology Publishing Group
2017-03-01
|
Series: | Oftalʹmologiâ |
Subjects: | |
Online Access: | https://www.ophthalmojournal.com/opht/article/view/356 |
id |
doaj-facd1db66f424b81bfbc3f497f212980 |
---|---|
record_format |
Article |
spelling |
doaj-facd1db66f424b81bfbc3f497f2129802021-07-29T08:55:25ZrusOphthalmology Publishing GroupOftalʹmologiâ 1816-50952017-03-01141677710.18008/1816-5095-2017-1-67-77328Long-term Results of Treatment of Patients with Non-proliferative Diabetic Retinopathy AngioprotectorsI. V. Vorobyeva0Federal State-Funded Educational Institution of Continuing Professional Education. Russian Medical Academy of Continuing Professional Education, Ministry of Healthcare of the Russian Federation; City Clinical Hospital named after S.P. Botkin, Moscow Public Health DepartmentPurpose: Optimization of approaches to the treatment of early stages diabetic retinopathy based on modern diagnosis and monitoring of patients with type 2 diabetes.Patients and methods: It was examined 90 patients (180 eyes) with type 2 diabetes with DR: women (74.4%) and men (25.6%), age 63,7±2,3 years. All groups matched by sex and age: Group 1 — control (healthy individuals without diabetes); Group 2 — Patients with DR0 (30 patients, 60 eyes) with type 2 diabetes without DR; 3 group — patients with DR I without DMO with type 2 diabetes (30 patients, 60 eyes). Patients 2 and 3 groups was treated with conservative treatment angioprotectors drug-Doxi-Hem® registered in Russia. The drug was administered in a dose of 500 mg three times a day for six months. Monitor patients for six months of receiving Doxi-Hem® preparation consisted of monthly conventional ophthalmic examination, including further analysis of BCVA (BCVA), light sensitivity of the macula (SM) as a result of fundusmikroperimetrii MAIA, central retinal thickness (PZT) based on the results of the optical coherence tomography (OCT). We take into account the compensation of diabetes on the level of glycated hemoglobin (HbA1C) blood.Results: When monitoring patients with type 2 diabetes to optimize the treatment of established efficacy and safety of drug therapy Doxi-Hem® in the prevention and treatment of pre-clinical and early manifestations of DR (DR0, DR1), which is confirmed by reliable positive dynamics of visual functions (BCVA, p <0.05, before treatment 0,8±0,02, after treatment increased to 0,92±0,02), morphological reduction in retinal thickness (PZT, p <0.05; before treatment 272,3±5,8 mm, after treatment 241.5±15.8 um), increased sensitivity of the macula (CM, p <0.05, before treatment 22.2±1.5 dB, after treatment 27.0±3.2 dB). Required control the severity of type 2 diabetes on the target level of blood glycosylated hemoglobin (HbA1C).Conclusion: Optimization approaches to HIV prevention, treatment of pre-clinical and early manifestations of DR (DR0, DR1) with the use of drug therapy angioprotector Doxi-Hem® based on modern diagnosis and monitoring of patients with type 2 diabetes for a long time will allow to stabilize and maintain clinical and morphological condition of the retina. Modern diagnostics, including the definition of the ophthalmological examination: visual acuity, central retinal thickness, macular light sensitivity as well as the definition and stabilization of important biochemical indicator of blood glycated hemoglobin (HbA1C) will not prevent the development of more severe stages of DR. In patients with type 2 diabetes without signs of diabetic retinopathy (DR0), while maintaining high visual acuity and normal retinal thickness showed a significant and meaningful reduction in the light sensitivity of the retina of the macula, which allows to start treatment with redox Doxi-Hem® at the preclinical stage (DR0).https://www.ophthalmojournal.com/opht/article/view/356diabetes mellitus type 2diabetic retinopatycalcium dobesilatedoxi-hem®fundusmicroperimetry maiacogerent optical tomography |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
I. V. Vorobyeva |
spellingShingle |
I. V. Vorobyeva Long-term Results of Treatment of Patients with Non-proliferative Diabetic Retinopathy Angioprotectors Oftalʹmologiâ diabetes mellitus type 2 diabetic retinopaty calcium dobesilate doxi-hem® fundusmicroperimetry maia cogerent optical tomography |
author_facet |
I. V. Vorobyeva |
author_sort |
I. V. Vorobyeva |
title |
Long-term Results of Treatment of Patients with Non-proliferative Diabetic Retinopathy Angioprotectors |
title_short |
Long-term Results of Treatment of Patients with Non-proliferative Diabetic Retinopathy Angioprotectors |
title_full |
Long-term Results of Treatment of Patients with Non-proliferative Diabetic Retinopathy Angioprotectors |
title_fullStr |
Long-term Results of Treatment of Patients with Non-proliferative Diabetic Retinopathy Angioprotectors |
title_full_unstemmed |
Long-term Results of Treatment of Patients with Non-proliferative Diabetic Retinopathy Angioprotectors |
title_sort |
long-term results of treatment of patients with non-proliferative diabetic retinopathy angioprotectors |
publisher |
Ophthalmology Publishing Group |
series |
Oftalʹmologiâ |
issn |
1816-5095 |
publishDate |
2017-03-01 |
description |
Purpose: Optimization of approaches to the treatment of early stages diabetic retinopathy based on modern diagnosis and monitoring of patients with type 2 diabetes.Patients and methods: It was examined 90 patients (180 eyes) with type 2 diabetes with DR: women (74.4%) and men (25.6%), age 63,7±2,3 years. All groups matched by sex and age: Group 1 — control (healthy individuals without diabetes); Group 2 — Patients with DR0 (30 patients, 60 eyes) with type 2 diabetes without DR; 3 group — patients with DR I without DMO with type 2 diabetes (30 patients, 60 eyes). Patients 2 and 3 groups was treated with conservative treatment angioprotectors drug-Doxi-Hem® registered in Russia. The drug was administered in a dose of 500 mg three times a day for six months. Monitor patients for six months of receiving Doxi-Hem® preparation consisted of monthly conventional ophthalmic examination, including further analysis of BCVA (BCVA), light sensitivity of the macula (SM) as a result of fundusmikroperimetrii MAIA, central retinal thickness (PZT) based on the results of the optical coherence tomography (OCT). We take into account the compensation of diabetes on the level of glycated hemoglobin (HbA1C) blood.Results: When monitoring patients with type 2 diabetes to optimize the treatment of established efficacy and safety of drug therapy Doxi-Hem® in the prevention and treatment of pre-clinical and early manifestations of DR (DR0, DR1), which is confirmed by reliable positive dynamics of visual functions (BCVA, p <0.05, before treatment 0,8±0,02, after treatment increased to 0,92±0,02), morphological reduction in retinal thickness (PZT, p <0.05; before treatment 272,3±5,8 mm, after treatment 241.5±15.8 um), increased sensitivity of the macula (CM, p <0.05, before treatment 22.2±1.5 dB, after treatment 27.0±3.2 dB). Required control the severity of type 2 diabetes on the target level of blood glycosylated hemoglobin (HbA1C).Conclusion: Optimization approaches to HIV prevention, treatment of pre-clinical and early manifestations of DR (DR0, DR1) with the use of drug therapy angioprotector Doxi-Hem® based on modern diagnosis and monitoring of patients with type 2 diabetes for a long time will allow to stabilize and maintain clinical and morphological condition of the retina. Modern diagnostics, including the definition of the ophthalmological examination: visual acuity, central retinal thickness, macular light sensitivity as well as the definition and stabilization of important biochemical indicator of blood glycated hemoglobin (HbA1C) will not prevent the development of more severe stages of DR. In patients with type 2 diabetes without signs of diabetic retinopathy (DR0), while maintaining high visual acuity and normal retinal thickness showed a significant and meaningful reduction in the light sensitivity of the retina of the macula, which allows to start treatment with redox Doxi-Hem® at the preclinical stage (DR0). |
topic |
diabetes mellitus type 2 diabetic retinopaty calcium dobesilate doxi-hem® fundusmicroperimetry maia cogerent optical tomography |
url |
https://www.ophthalmojournal.com/opht/article/view/356 |
work_keys_str_mv |
AT ivvorobyeva longtermresultsoftreatmentofpatientswithnonproliferativediabeticretinopathyangioprotectors |
_version_ |
1721251110194249728 |